ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
May 20, 2021 14:36 JST
Source:
Apollomics, Inc.
APOLLOMICS INC. ANNOUNCES OFFICIAL OPENING OF SHANGHAI BRANCH
Foster City, CA, Shanghai and Hangzhou, China, May 20, 2021 - (ACN Newswire) - Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced that Apollomics Shanghai Branch has been officially opened and started its operations at Zhangjiang Hi-Tech Park, Pudong District, Shanghai.
Dr. Guoliang Yu, the company's Co-Founder, Chairman and CEO said, "In 2018, we established a Chinese company in Hangzhou, and our Chinese team has grown from a few people to dozens of people. The Shanghai branch is located in the Silicon Valley of bioinnovative drugs in China, Zhangjiang Medicine Valley, which has gathered top talent from research and development, clinical and commercialization. Many of our clinical trials in China are soon to be carried out. The establishment of the Shanghai branch will be more conducive to the construction of our diverse talent team and will also promote connection and communication with domestic and foreign partners."
About Apollomics, Inc.
Apollomics, Inc. is an innovative biopharmaceutical company committed to the discovery and development of monotherapies and combination therapies of tumor-targeting agents and immuno-oncology agents. It has operating entities in Foster City, California, USA and Hangzhou, China. The company's product pipeline has many projects at different stages of development, including novel, humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. For more information, please visit www.apollomicsinc.com.
Contact information of Apollomics:
Investor Contact:
Wilson W. Cheung
Chief Financial Officer
Telephone: +1-650-209-4436
Email:
wcheung@apollomicsinc.com
Company Contact:
Liping Zhang
Telephone: +86-571-83521933
Email:
liping.zhang@apollomicsinc.com
U.S. Media Contact:
Remy Bernarda
Corporate Communications
(415) 203-6386
remy.bernarda@apollomicsinc.com
China Media Contact:
Porda Havas International Finance Communications Group
Kelly Fung
General Manager
Telephone: (852) 3150 6763
Email:
kelly.fung@pordahavas.com
Phoenix Fung
Assistant Vice President
Telephone: (852) 3150 6773
Email:
phoenix.fung@pordahavas.com
Source: Apollomics, Inc.
Sectors: BioTech, Healthcare & Pharm
Copyright ©2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
Galaxy Payroll Group Limited and People Intelligence Singapore Pte. Ltd. Announce Strategic Partnership
Jan 03, 2025 20:41 JST
Gruelling Challenge Awaits TGR In Saudi Arabia
Dec 27, 2024 15:20 JST
The General Incorporated Association Generative AI Japan Announces the Winners of the Japan Generative AI Award 2024
Dec 27, 2024 11:00 JST
MHI Included in "World Index" of Dow Jones Sustainability Index for Second Consecutive Year
Dec 27, 2024 09:36 JST
TOYOTA GAZOO Racing to Exhibit at Tokyo Auto Salon 2025
Dec 26, 2024 17:11 JST
JCB Launches Red Guahan Shopping Mall Shuttle Free Ride Promotion in Guam
Dec 26, 2024 12:00 JST
Mazda Production and Sales Results for November 2024
Dec 26, 2024 11:46 JST
MHI Conducts Nighttime and Long-Distance Highway Demonstration Testing of Unmanned Aerial Vehicle Currently Under Development
Dec 26, 2024 09:47 JST
Hitachi delivers a turnkey rail solution for Ho Chi Minh City's first urban railway Line 1 in Vietnam
Dec 24, 2024 13:19 JST
Nissan and Honda sign MOU to consider business integration
Dec 24, 2024 11:18 JST
Olympus Named to Dow Jones Sustainability World Index for the Fourth Consecutive Year
Dec 24, 2024 11:00 JST
GAC Honda Begins Operation of New Energy Vehicle (NEV) Production Factory in Guangzhou, China
Dec 24, 2024 10:23 JST
Sarawak Premier Makes Inaugural Visit to Mitsubishi Power's Takasago Hydrogen Park
Dec 24, 2024 10:10 JST
Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases
Dec 23, 2024 17:22 JST
Nissan, Honda, and Mitsubishi Motors sign MOU on collaborative considerations
Dec 23, 2024 13:54 JST
Fujitsu drives chemical industry logistics DX with participation in joint logistics demonstration
Dec 23, 2024 13:30 JST
Mitsubishi Motors Cumulative Production Reaches One Million Units in Indonesia
Dec 20, 2024 17:35 JST
Contract Renewed on Operation and Maintenance (O&M) Services for APM System at Washington Dulles International Airport
Dec 20, 2024 17:24 JST
Toyota Launches Alphard and Vellfire PHEV Models in Japan
Dec 20, 2024 15:38 JST
6G Begins! Embarking on a New Journey of Global Interoperable Standards
Dec 19, 2024 16:50 JST
More Latest Release >>
Related Release
Apollomics, a Company Developing Novel Oncology Therapies to Address Difficult-to-Treat Cancers, Announces Closing of Business Combination and Listing on Nasdaq
March 30 2023 20:29 JST
Apollomics Inc. Expands Leadership Team with Appointment of Jane Wang, PhD as Chief Scientific Officer
July 26 2022 09:17 JST
Apollomics Inc. to Host Virtual Investor Events on Wednesday, January 26, 2022 and Thursday, January 27, 2022
January 12 2022 09:25 JST
Apollomics Inc. Announces CEO Guo-Liang Yu, PhD Appointed as Chairman of the Board for the BayHelix Group
January 04 2022 10:10 JST
Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial with APL-106 (Uproleselan Injection) in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
November 22 2021 10:40 JST
Edison Oncology and Apollomics Announce Treatment of First Patient by EO1001 (APL-122) in a Phase I/IIa Clinical Trial
October 01 2021 10:00 JST
Apollomics, Inc. Doses First Patient in a Phase I Clinical Trial of APL-102
August 10 2021 11:53 JST
Apollomics, Inc. Appoints Seasoned Healthcare Executive K. Peony Yu, M.D., as Chief Medical Officer
March 09 2021 10:35 JST
Apollomics, Inc Announces Enrollment of First Patient in Phase 1 Clinical Trial of APL-106 (uproleselan injection) in China
March 04 2021 11:30 JST
Apollomics, Inc. Licenses a Targeted, Active Checkpoint Control Immunotherapy for Greater China and South Africa
February 12 2021 13:00 JST
More Press release >>